Virax Biolabs
VRAX
4 hedge funds and large institutions have $10.9K invested in Virax Biolabs in 2023 Q3 according to their latest regulatory filings, with 3 funds opening new positions, increasing their positions, 0 reducing their positions, and 3 closing their positions.
0% more funds holding
Funds holding: 4 → 4 (0)
0% less ownership
Funds ownership: 0% → 0% (-0%)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
52% less capital invested
Capital invested by funds: $22.8K → $10.9K (-$11.9K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$6.09K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$5.62K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$94 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$10K |
| 2 |
TSS
Two Sigma Securities
New York
|
-$7.08K |
| 3 |
Millennium Management
New York
|
-$4.9K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Citadel Advisors
Miami,
Florida
| $5.32K | +$6.09K | +65 | New |
|
|
2
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $4.88K | +$5.62K | +60 | New |
|
3
Wells Fargo
San Francisco,
California
| $650 | – | – | – |
|
|
4
UBS Group
Zurich,
Switzerland
| $48 | +$94 | +1 | New |
|
|
5
Renaissance Technologies
New York
| – | -$10K | -98 | Closed |
|
|
TSS
6
Two Sigma Securities
New York
| – | -$7.08K | -73 | Closed |
|
|
7
Millennium Management
New York
| – | -$4.9K | -50 | Closed |
|
VRAX Hedge Fund Activity: Q3 2023 in Review
4 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Virax Biolabs (VRAX) for Q3 2023, worth a combined $10.9K — down 52% from $22.8K a quarter earlier.
Fund positioning in VRAX was balanced in Q3 2023: 3 funds opened new positions, 3 closed out, 0 added to existing stakes and 0 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $6.09K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $10K sold.
- 4 institutional investors held Virax Biolabs (VRAX) as of Q3 2023, unchanged from Q2 2023.
- Funds reported $10.9K of Virax Biolabs stock for Q3 2023, down 52% quarter-over-quarter.
- 3 funds opened new Virax Biolabs positions in Q3 2023 and 3 closed out, a net change of 0 holders.
- The largest Virax Biolabs buyer in Q3 2023 was Citadel Advisors, an estimated $6.09K added.
- The largest Virax Biolabs seller in Q3 2023 was Renaissance Technologies, an estimated $10K sold.
Based on aggregated 13F filings for Q3 2023.